First Trust Advisors LP Has $220.53 Million Position in Amgen, Inc. (NASDAQ:AMGN)

First Trust Advisors LP increased its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 37.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,196,708 shares of the medical research company’s stock after purchasing an additional 325,404 shares during the period. First Trust Advisors LP owned approximately 0.20% of Amgen worth $220,529,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Bray Capital Advisors lifted its holdings in Amgen by 11.6% during the 2nd quarter. Bray Capital Advisors now owns 19,676 shares of the medical research company’s stock worth $3,626,000 after purchasing an additional 2,045 shares during the last quarter. Weaver Consulting Group bought a new position in Amgen during the 1st quarter worth $239,000. CHICAGO TRUST Co NA increased its stake in Amgen by 2.8% during the 2nd quarter. CHICAGO TRUST Co NA now owns 3,716 shares of the medical research company’s stock worth $685,000 after acquiring an additional 100 shares during the period. Phocas Financial Corp. bought a new position in Amgen during the 4th quarter worth $117,000. Finally, Calton & Associates Inc. increased its stake in Amgen by 17.8% during the 2nd quarter. Calton & Associates Inc. now owns 1,770 shares of the medical research company’s stock worth $326,000 after acquiring an additional 268 shares during the period. 77.43% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts have commented on the company. Royal Bank of Canada restated a “neutral” rating and set a $192.00 price objective on shares of Amgen in a research note on Tuesday, May 21st. BMO Capital Markets set a $230.00 price objective on Amgen and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Mizuho restated a “buy” rating and set a $208.00 price objective on shares of Amgen in a research note on Monday, July 1st. Credit Suisse Group assumed coverage on Amgen in a research note on Monday, May 20th. They set an “outperform” rating and a $208.00 price objective on the stock. Finally, JPMorgan Chase & Co. restated a “hold” rating and set a $190.00 price objective on shares of Amgen in a research note on Wednesday, May 15th. Eight analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $210.41.

In other news, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $175.68, for a total value of $351,360.00. Following the transaction, the director now owns 16,219 shares in the company, valued at approximately $2,849,353.92. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director R Sanders Williams sold 425 shares of Amgen stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total value of $77,792.00. Following the completion of the transaction, the director now owns 16,336 shares in the company, valued at approximately $2,990,141.44. The disclosure for this sale can be found here. In the last quarter, insiders sold 4,425 shares of company stock worth $804,312. Corporate insiders own 0.25% of the company’s stock.

Shares of AMGN opened at $196.25 on Friday. Amgen, Inc. has a 52-week low of $166.30 and a 52-week high of $210.19. The firm has a fifty day simple moving average of $181.68. The company has a debt-to-equity ratio of 2.58, a quick ratio of 2.60 and a current ratio of 2.89. The company has a market cap of $110.07 billion, a price-to-earnings ratio of 13.63, a price-to-earnings-growth ratio of 2.15 and a beta of 1.19.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, July 30th. The medical research company reported $3.97 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.58 by $0.39. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The company had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.67 billion. During the same quarter last year, the company posted $3.83 EPS. The company’s revenue for the quarter was down 3.1% compared to the same quarter last year. On average, equities analysts expect that Amgen, Inc. will post 14.23 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 6th. Stockholders of record on Thursday, August 15th will be paid a $1.45 dividend. The ex-dividend date is Wednesday, August 14th. This represents a $5.80 annualized dividend and a dividend yield of 2.96%. Amgen’s payout ratio is 40.28%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Recommended Story: Gross Domestic Product (GDP)

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.